SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Drug Development
Rare Disease Companies Unite to Advocate for Life-Changing Therapies
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
May 13, 2021
 · 
4 min read
 · 
Kate Goodwin
Deals
Money on the Move: May 5 - 11
Catch up on the investment news quickly with BioSpace’s brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week.
May 12, 2021
 · 
7 min read
 · 
Kate Goodwin
Business
Three Companies Land Fresh Funds to Advance Pipelines
2021 is shaping up to be another banner year for biotech companies as they advance the next gen technologies and therapeutics for the health of all. Here’s a few raking in cash for their programs today.
May 11, 2021
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Researchers Concerned Over Long Covid Effects on Communities of Color
Researchers are now concerned that the same health inequalities that have made certain racial and ethnic groups experience higher infection and death rates also drive disparities in treatment for long Covid.
May 10, 2021
 · 
4 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Deals
IPO and SPAC Boom Continues as More Life Sciences Companies Announce Terms
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
May 7, 2021
 · 
3 min read
 · 
Kate Goodwin
Drug Development
How Mix-n-Match Vaccines Could Offer Better Protection Against COVID-19
While mix-and-match sounds more like a meal deal at your local fast-food chain, it’s now the colloquial term being used for the approach currently under study in the U.K. for administering two doses of different types of COVID-19 vaccines.
May 6, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Money on the Move: April 29 – May 4
April showers bring May dollars. Here’s whose cash gardens are really blooming this week in the life sciences world.
May 5, 2021
 · 
5 min read
 · 
Kate Goodwin
Drug Development
Is the Dream of COVID-19 “Herd Immunity” Dead?
In 2020, “herd immunity” was the mythical goal set forth in the hearts and minds of a struggling population, waiting on a vaccine to return us to normal. Now experts are saying herd immunity with COVID-19 may well be impossible.
May 4, 2021
 · 
4 min read
 · 
Kate Goodwin
Business
Already on Fast Track, Aceragen Launches with $35 Million and Farber Disease Drug
Grabbing a fast-tracked novel enzyme replacement therapy for a rare pediatric disease, new biopharma Aceragen launched with $35 million in hand for product financing.
May 3, 2021
 · 
2 min read
 · 
Kate Goodwin
Bodo Marks/picture alliance via Getty Images
Policy
AstraZeneca Hits Another Bump in the Road to COVID-19 Vaccine Approval in the US
AstraZeneca’s COVID-19 vaccine road to approval has been anything but smooth.
April 30, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Biden Proposes New $6.5 Billion Advanced Research Agency to End Cancer
Cancer doesn’t care if you’re Democratic, Republican, Libertarian or Green. It strikes without prejudice or consideration. As President Joe Biden said Wednesday night in his first major speech to Congress, “I know of nothing that is more bipartisan.”
April 29, 2021
 · 
2 min read
 · 
Kate Goodwin
Biotech Bay
With Anti-CD47 Cancer Drugs Trending, Arch Takes in $105 Million for its Antibody
The race is on in the CD47 field, and Brisbane-based player Arch Oncology just upped the bet with a $105 million Series C raise.
April 27, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Two Research Leaders Share How CSL Behring Empowers Teams Across the Globe
As a devastating pandemic increased scientific collaboration globally, CSL was already ahead of the curve with teams spanning the continents, working together to advance lifesaving treatments and technologies.
April 27, 2021
 · 
4 min read
 · 
Kate Goodwin
stop sign with black board backround
Lack of Funding Drives Biotech to Suspend Drug-Resistant Antibiotic Pipeline
Five-year-old X-Biotix announced it is throwing in the towel on its antibacterial research efforts and changing gears for its corporate strategy.
April 26, 2021
 · 
2 min read
 · 
Kate Goodwin
Pharm Country
New Drug Boosts Brain Cell Cleanup to Combat Neurodegenerative Diseases
Researchers from Albert Einstein’s College of Medicine are excited with the recently published findings of an experimental drug that reversed key symptoms of Alzheimer’s disease in mice.
April 23, 2021
 · 
3 min read
 · 
Kate Goodwin
Load More